Effects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Zhu, Yong Ming ^a   Azahri, Nor Saadah M ^a   Yu, Danny C W ^a   Woll, Penella J ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; INTERLEUKIN 8; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2; SMALL INTERFERING RNA; VASCULOTROPIN; PROSTAGLANDIN SYNTHASE INHIBITOR; VASCULOTROPIN A;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; WESTERN BLOTTING; CELL PROLIFERATION; DISEASE COURSE; GENE EXPRESSION REGULATION; LUNG TUMOR; METABOLISM; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; SMALL CELL CARCINOMA; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-8; LUNG NEOPLASMS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 49949098279     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-218     Document Type: Article

References (32)

1. Kim HS Youm HR Lee JS Min KW Chung JH Park CS Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer Lung Cancer 2003, 42:163-170. 10.1016/S0169-5002(03)00290-3 14568683
2. Yuan A Yu CJ Chen WJ Lin FY Kuo SH Luh KT Yang PC Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer Int J Cancer 2000, 89:475-483. 10.1002/ 1097-0215(20001120)89:6<475::AID-IJC2>3.0.CO;2-T 11102890.
3. Mall JW Schwenk W Philipp AW Meyer-Kipker C Mall W Muller J Pollmann C Serum vascular endothelial growth factor levels correlate better with tumour stage in small cell lung cancer than albumin, neuron-specific enolase or lactate dehydrogenase Respirology 2002, 7:99-102. 10.1046/ j.1440-1843.2002.00386.x 11985730
4. Fontanini G Faviana P Lucchi M Boldrini L Mussi A Camacci T Mariani MA Angeletti CA Basolo F Pingitore R A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma Br J Cancer 2002, 86:558-563. 10.1038/sj.bjc.6600130 11870537
5. Salven P Ruotsalainen T Mattson K Joensuu H High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer Int J Cancer 1998, 79:144-146 10.1002/(SICI)1097-0215(19980417)79:2<144::AID-IJC8>3.0.CO;2-T 9583728
6. Tanno S Ohsaki Y Nakanishi K Toyoshima E Kikuchi K Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3 Lung Cancer 2004, 46:11-19. 10.1016/j.lungcan.2004.03.006 15364128
7. Sandler A Gray R Perry MC Brahmer J Schiller JH Dowlati A Lilenbaum R Johnson DH Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 2006, 355:2542-2550. 10.1056/ NEJMoa061884 17167137
8. Yuan A Yang PC Yu CJ Chen WJ Lin FY Kuo SH Luh KT Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer Am J Respir Crit Care Med 2000, 162:1957-1963. 11069840
9. Masuya D Huang C Liu D Kameyama K Hayashi E Yamauchi A Kobayashi S Haba R Yokomise H The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients Cancer 2001, 92:2628-38. 10.1002/ 1097-0142(20011115)92:10<2628::AID-CNCR1616>3.0.CO;2-F 11745198
10. Orditura M De Vita F Catalano G Infusino S Lieto E Martineli E Morgillo F Castellano P Pignatelli C Gaizia G Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis J Interferon Cytokine Res 2002, 22:1129-1135. 10.1089/10799900260442557 12513912
11. Chen JJ Yao PL Yuan A Hong TM Shun CT Kuo ML Lee YC Yang PC Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: Its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer Clin Cancer Res 2003, 9:729-737. 12576442
12. Zhu YM Webster SJ Flower D Woll PJ Interleukin-8/CXCL8 is a growth factor for human lung cancer cells Br J Cancer 2004, 91:1970-1976. 10.1038/sj.bjc.6602227 15545974
13. Zhu YM Woll PJ Mitogenic effects of interleukin-8/CXCL8 on cancer cells Future Oncol 2005, 1:699-704. 10.2217/14796694.1.5.699 16556047
14. Xie K Interleukin-8 and human cancer biology Cytokine Growth Factor Rev 2001, 12:375-391. 10.1016/S1359-6101(01)00016-8 11544106
15. Wolff H Saukkonen K Anttila S Karjalainen A Vainio H Ristimaki A Expression of cyclooxygenase-2 in human lung carcinoma Cancer Res 1998, 58:4997-5001. 9823297
16. Brown JR DuBois RN Cyclooxygenase as a target in lung cancer Clin Cancer Res 2004, 10:4266s-4269s. 10.1158/1078-0432.CCR-040014 15217972
17. Petkova DK Clelland C Ronan J Pang L Coulson JM Lewis S Knox AJ Overexpression of cyclooxygenase-2 in non-small cell lung cancer Respir Med 2004, 98:164-172. 10.1016/j.rmed.2003.09.006 14971881
18. Mascaux C Martin B Paesmans M Berghmans T Dusart M Haller A Lothaire P Meert AP Lafitte JJ Sculier JP Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results Br J Cancer 2006, 95:139-145. 10.1038/sj.bjc.6603226 16786043
19. Yuan A Yu CJ Shun CT Luh KT Kuo SH Lee YC Yang PC Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients Int J Cancer 2005, 115:545-555. 10.1002/ijc.20898 15704107
20. Pold M Zhu LX Sharma S Burdick MD Lin Y Lee PP Pold A Luo J Krysan K Dohadwala M Mao JT Batra RK Strieter RM Dubinett SM Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer Cancer Res 2004, 64:1853-1860. 10.1158/ 0008-5472.CAN-03-3262 14996749
21. Subbaramaiah K Dannenberg AJ Cyclooxygenase 2: A molecular target for cancer prevention and treatment TRENDS in Pharmacol Sci 2003, 24:96-102. 10.1016/S0165-6147(02)00043-3
22. Futaki N Takahashi S Yokoyama M Arai I Higuchi S Otomo S NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/ cyclooxygenase (COX-2) activity in vitro Prostaglandins 1994, 47:55-59. 10.1016/0090-6980(94)90074-4 8140262
23. Tas F Duranyildiz D Oguz H Camlica H Yasasever V Topuz E Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer Cancer Invest 2006, 24:492-496. 10.1080/ 07357900600814771 16939957
24. Tas F Duranyildiz D Oguz H Camlica H Yasasever V Topuz E Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer Cancer Invest 2006, 24:576-580. 10.1080/ 07357900600894781 16982461
25. Coggins KG Latour A Nguyen MS Audoly L Coffman TM Koller BH Metabolism of PGE2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus Nat Med 2002, 8:91-92. 10.1038/nm0202-91 11821873
26. Shin YK Park JS Kim HS Jun HJ Kim GH Suh CO Yun YS Pyo H Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels Cancer Res 2005, 65:9501-9509. 10.1158/0008-5472.CAN-05-0220 16230415
27. Dowell JE Amirkhan RH Lai WS Frawley WH Minna JD Survival in small cell lung cancer is independent of tumor expression of VEGF and COX-2 Anticancer Res 2004, 24:2367-73. 15330186
28. Dalwadi H Krysan K Heuze-Vourc'h N Dohadwala M Elashoff D Sharma S Cacalano N Lichtenstein A Dubinett S Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer Clin Cancer Res 2005, 11:7674-7682. 10.1158/1078-0432.CCR-05-1205 16278387
29. Sanchez-Alcazar JA Bradbury DA Pang L Knox AJ Cyclooxygenase (COX) inhibitors induce apoptosis in non-small cell lung cancer through cyclooxygenase independent pathways Lung Cancer 2003, 40:33-44. 10.1016/ S0169-5002(02)00530-5 12660005
30. Pyo H Choy H Amorino GP Kim JS Cao Q Hercules SK DuBois RN A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2 Clin Cancer Res 2001, 7:2998-3005. 11595687
31. Raut CP Nawrocki S Lashinger LM Davis DW Khanbolooki S Xiong H Ellis LM McConkey DJ Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts Cancer Biol Ther 2004, 3(12):1217-1224. 15477758
32. Singh B Berry JA Vincent LE Lucci A Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer J Surg Res 2006, 134:44-51. 10.1016/j.jss.2006.03.018 16678856